Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-30
DOI
10.1038/s41571-019-0267-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunologic correlates of the abscopal effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 inhibition and radiotherapy
- (2019) Mrinal M. Gounder et al. CLINICAL CANCER RESEARCH
- MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas
- (2019) Ophélia Maertens et al. Cancer Discovery
- Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
- (2019) Helai P. Mohammad et al. NATURE MEDICINE
- Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer.
- (2019) Adrian Gerard Murphy et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer
- (2019) Benjamin P. Levy et al. EUROPEAN JOURNAL OF CANCER
- EZH2 inhibitor GSK126 suppresses anti-tumor immunity by driving production of myeloid-derived suppressor cells
- (2019) Shuo Huang et al. CANCER RESEARCH
- The histone chaperone CAF-1 cooperates with the DNA methyltransferases to maintain Cd4 silencing in cytotoxic T cells
- (2019) Charles Ng et al. GENES & DEVELOPMENT
- Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Long-term follow-up of a phase 1b study.
- (2019) Rahul Raj Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Zefei Jiang et al. LANCET ONCOLOGY
- High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer
- (2019) Kevin Grosselin et al. NATURE GENETICS
- Epigenetic modifiers as new immunomodulatory therapies in solid tumours
- (2018) S Aspeslagh et al. ANNALS OF ONCOLOGY
- BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
- (2018) Chaoyang Sun et al. CANCER CELL
- BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC
- (2018) Brandon Leonard et al. CANCER RESEARCH
- Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response In Osteosarcoma
- (2018) Binghao Li et al. CANCER RESEARCH
- LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
- (2018) Wanqiang Sheng et al. CELL
- The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer
- (2018) Andrew J. Wilson et al. GYNECOLOGIC ONCOLOGY
- PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
- (2018) Linglong Yin et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
- (2018) David R. Spigel et al. Journal of Thoracic Oncology
- Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
- (2018) Antoine Italiano et al. LANCET ONCOLOGY
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- The epigenetic control of stemness in CD8+T cell fate commitment
- (2018) Luigia Pace et al. SCIENCE
- The Expanding World of N-MYC–Driven Tumors
- (2018) David S. Rickman et al. Cancer Discovery
- Pharmacological targeting of BET proteins attenuates radiation-induced lung fibrosis
- (2018) Jian Wang et al. Scientific Reports
- LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer
- (2018) T. Boulding et al. Scientific Reports
- Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer
- (2018) Aishwarya Pawar et al. Cell Reports
- The pivotal role of DNA methylation in the radio-sensitivity of tumor radiotherapy
- (2018) Xueru Zhu et al. Cancer Medicine
- Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
- (2018) Kristin C. Hicks et al. OncoImmunology
- Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS
- (2018) Shunsuke Kitajima et al. CANCER CELL
- Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
- (2018) Xun Huang et al. CELL
- Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
- (2018) Sangeeta Goswami et al. JOURNAL OF CLINICAL INVESTIGATION
- ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.
- (2018) Nilofer Saba Azad et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
- (2018) Andreas Nicholas Saltos et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II trial of pembrolizumab(P) and vorinostat(V) in recurrent metastatic head and neck squamous cell carcinomas (HN) and salivary gland cancer (SGC).
- (2018) Cristina P. Rodriguez et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.
- (2018) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Epigenetic control of innate and adaptive immune memory
- (2018) Colleen M. Lau et al. NATURE IMMUNOLOGY
- Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
- (2018) Gonzalo Recondo et al. Nature Reviews Clinical Oncology
- Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade
- (2018) Ye Qin et al. ONCOGENE
- BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors
- (2018) Garrett W. Rhyasen et al. PLoS One
- Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling
- (2018) Amanda Balboni Iniguez et al. CANCER CELL
- Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance
- (2018) Piyush B. Gupta et al. Cell Stem Cell
- Sensitive tumour detection and classification using plasma cell-free DNA methylomes
- (2018) Shu Yi Shen et al. NATURE
- High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer
- (2018) Keith H. Jansson et al. Scientific Reports
- Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity
- (2018) Kelsey E. Sivick et al. Cell Reports
- Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
- (2018) Brian J. Christmas et al. Cancer Immunology Research
- Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
- (2018) Anna C. Ferrari et al. CLINICAL CANCER RESEARCH
- Oncohistones: drivers of pediatric cancers
- (2017) Faizaan Mohammad et al. GENES & DEVELOPMENT
- HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
- (2017) Stuart J. Gallagher et al. INTERNATIONAL JOURNAL OF CANCER
- Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies
- (2017) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state
- (2017) Mohammad Fallahi‐Sichani et al. Molecular Systems Biology
- Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
- (2017) Sydney M. Shaffer et al. NATURE
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues
- (2017) M Ryan Corces et al. NATURE METHODS
- Drugs that lack single-agent activity: are they worth pursuing in combination?
- (2017) Bishal Gyawali et al. Nature Reviews Clinical Oncology
- Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02
- (2017) Evanthia Galanis et al. NEURO-ONCOLOGY
- Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
- (2017) Meredith L. Stone et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The cancer epigenome: Concepts, challenges, and therapeutic opportunities
- (2017) Mark A. Dawson SCIENCE
- A comprehensive review of lysine-specific demethylase 1 and its roles in cancer
- (2017) Amir Hosseini et al. Epigenomics
- mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors
- (2017) Clare F. Malone et al. Cancer Discovery
- BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
- (2017) Sergey Karakashev et al. Cell Reports
- HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma
- (2016) Yanxin Pei et al. CANCER CELL
- Intratumoral Heterogeneity of the Epigenome
- (2016) Tali Mazor et al. CANCER CELL
- Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer
- (2016) Azusa Tanimoto et al. CLINICAL CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study
- (2016) Michael Bitzer et al. JOURNAL OF HEPATOLOGY
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
- (2016) I. A. Asangani et al. MOLECULAR CANCER RESEARCH
- Chromatin Regulators as a Guide for Cancer Treatment Choice
- (2016) Zachary A. Gurard-Levin et al. MOLECULAR CANCER THERAPEUTICS
- Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer
- (2016) Emily Chan et al. RADIOTHERAPY AND ONCOLOGY
- Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
- (2016) A. Stathis et al. Cancer Discovery
- Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations
- (2016) Brendon Ladd et al. Oncotarget
- Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
- (2016) Alison M. Kurimchak et al. Cell Reports
- BET and BRAF inhibitors act synergistically againstBRAF-mutant melanoma
- (2016) Luca Paoluzzi et al. Cancer Medicine
- The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat
- (2016) Yusuke Tomita et al. OncoImmunology
- Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement
- (2015) Surojeet Sengupta et al. BREAST CANCER RESEARCH AND TREATMENT
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer
- (2015) Ji-Youn Han et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer
- (2015) E. H. Bell et al. CLINICAL CANCER RESEARCH
- Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma
- (2015) S. G. DuBois et al. CLINICAL CANCER RESEARCH
- HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL
- (2015) R. Carson et al. CLINICAL CANCER RESEARCH
- Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors
- (2015) Matthew Zibelman et al. INVESTIGATIONAL NEW DRUGS
- Single-cell chromatin accessibility reveals principles of regulatory variation
- (2015) Jason D. Buenrostro et al. NATURE
- EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors
- (2015) Christine M. Fillmore et al. NATURE
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
- (2015) Francois Le Loarer et al. NATURE GENETICS
- SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
- (2015) Kimberly H Kim et al. NATURE MEDICINE
- Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma
- (2015) E. Q. Lee et al. NEURO-ONCOLOGY
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
- (2015) Vanesa Nogales et al. Oncotarget
- Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
- (2015) Timothy J. Stuhlmiller et al. Cell Reports
- SWI/SNF complexes are required for full activation of the DNA-damage response
- (2015) Stephanie L. Smith-Roe et al. Oncotarget
- Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
- (2015) Kyungsoo Ha et al. Oncotarget
- A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
- (2014) R M Glasspool et al. BRITISH JOURNAL OF CANCER
- Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma
- (2014) Edwin Choy et al. CANCER
- An epigenomic approach to therapy for tamoxifen-resistant breast cancer
- (2014) Qin Feng et al. CELL RESEARCH
- Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer
- (2014) You-Wei Zhang et al. Epigenetics
- Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey
- (2014) Xavier Paoletti et al. EUROPEAN JOURNAL OF CANCER
- Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer
- (2014) Panagiotis A. Konstantinopoulos et al. GYNECOLOGIC ONCOLOGY
- Cancer epigenetics drug discovery and development: the challenge of hitting the mark
- (2014) Robert M. Campbell et al. JOURNAL OF CLINICAL INVESTIGATION
- Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
- (2014) Hariharan Easwaran et al. MOLECULAR CELL
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
- (2014) Jessica E. Bolden et al. Cell Reports
- Bromodomain Protein BRD4 Is Required for Estrogen Receptor-Dependent Enhancer Activation and Gene Transcription
- (2014) Sankari Nagarajan et al. Cell Reports
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
- (2013) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling
- (2013) K. T. Thurn et al. MOLECULAR CANCER THERAPEUTICS
- A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
- (2013) Cory M. Johannessen et al. NATURE
- Epigenetic Resensitization to Platinum in Ovarian Cancer
- (2012) D. Matei et al. CANCER RESEARCH
- Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
- (2012) Samir E. Witta et al. JOURNAL OF CLINICAL ONCOLOGY
- TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer
- (2012) Ning Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
- (2012) King Pan Ng et al. NATURE MEDICINE
- Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling
- (2012) C Zeller et al. ONCOGENE
- EZH2 silencing with RNAi enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo
- (2012) HUI XIA et al. Oncology Letters
- Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy
- (2011) Scott Thomas et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?
- (2011) Sophie Postel-Vinay et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
- (2011) J. Drappatz et al. JOURNAL OF NEURO-ONCOLOGY
- Androgen receptor overexpression alters binding dynamics of the receptor to chromatin and chromatin structure
- (2011) Alfonso Urbanucci et al. PROSTATE
- Versatility of PRMT5-induced methylation in growth control and development
- (2011) Vrajesh Karkhanis et al. TRENDS IN BIOCHEMICAL SCIENCES
- Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
- (2010) Siqing Fu et al. CANCER
- Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry
- (2010) María Berdasco et al. DEVELOPMENTAL CELL
- Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels
- (2009) D. Mahalingam et al. CLINICAL CANCER RESEARCH
- ChIP-Seq of ERα and RNA polymerase II defines genes differentially responding to ligands
- (2009) Willem-Jan Welboren et al. EMBO JOURNAL
- Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis
- (2009) F. Bruzzese et al. MOLECULAR CANCER THERAPEUTICS
- Epigenetic inheritance during the cell cycle
- (2009) Aline V. Probst et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeting tumor angiogenesis with histone deacetylase inhibitors
- (2008) Leigh Ellis et al. CANCER LETTERS
- Role of Acetylation and Extracellular Location of Heat Shock Protein 90 in Tumor Cell Invasion
- (2008) Y. Yang et al. CANCER RESEARCH
- Postradiation Sensitization of the Histone Deacetylase Inhibitor Valproic Acid
- (2008) P. Chinnaiyan et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More